

Dennis A Bloomfield, Bao-Gan Peng, Sandro Vento

Editor-in-Chief

World Journal of Clinical Cases

Baishideng Publishing Group Inc

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

February 10, 2021

Dear Prof. Dennis A Bloomfield, Bao-Gan Peng, Sandro Vento

We are grateful for the opportunity to resubmit our revised manuscript (attached) entitled "**Combined Immune Checkpoint Inhibitors of CTLA4 and PD-1 for Hepatic Melanoma of Unknown Primary Origin: A Case Report**" (Manuscript No.: 61472). We have modified our manuscript as suggested by the editor and reviewers. The revised manuscript has been read and approved by all authors.

We have addressed the comments raised by the reviewers and highlighted the changes in red color. Our point by point responses to the reviewers' comments are listed below. We hope that the revised manuscript is now acceptable for publication in the **World Journal of Clinical Cases**.

We will be happy to make any further revisions, if necessary, or clarify any questions that you may have.

Sincerely yours,

Shih YuLueng

Yu-Lueng Shih, M.D. Ph.D., Associated Professor

Graduate Institute of Medical Sciences; and Division of Gastroenterology,
Department of Internal Medicine, Tri-Service General Hospital, National
Defense Medical Center, No.161, Section 6, Minquan East Road, Neihu
District, Taipei City 11490, Taiwan, Republic of China.

E-mail: albreb@ms28.hinet.net

Tel: +886-2-87917654; Fax: +886-2-87917654

Reviewer #1:

In the present form, the manuscript is ready for publishing.

Reviewer #2:

The author gives a complete introduction of the treatment of hepatic melanoma, a rare disease. This paper introduces the treatment and effect of this case, which has certain reference value for the treatment of this disease.

Response to Reviewer 1# and 2#:

We greatly appreciate the positive comments and suggestions from you.